| Lifestyle Drugs - New Opportunities in Obesity |
|---|
 |
| Publisher: | Nicholas Hall & Company |
| Year of publication: | 2001 |
| Type of publication: | Market report |
| Publisher's reference (if any): | N/A |
| Author(s): | Sreten Bogdanovic and Beata Langlands |
| Approximate page count: | 75 |
| Price when published: | £1,875 |
Remarks:
- Page numbers, where given, refer to the draft manuscript (which may differ from the published version).
- The copyright in this report is owned by the publisher, to whom any requests for copies should be addressed.
- This report is one of three modules; all modules are also available as a single volume, priced at £5,000.
|
TABLE OF CONTENTS
Page
About the authors v
Table of contents vii
List of tables xvii
EMERGING TRENDS SHAPING THE LIFESTYLE DRUGS MARKET
1 Patient-initiated-prescribing (PIP):
implications for the OTC market 1
2 Prospects for Rx-to-OTC switches of lifestyle drugs 1
2.1 The Rx-to-OTC movement 1
2.2 The likely role of consumers 2
2.3 The likely role of economic factors 4
2.4 Possible candidates for Rx-to-OTC switches 4
3 The advent of direct-to-customer (DTC) advertising 6
3.1 The rapidly growing US DTC advertising market 6
3.2 The prospects for DTC advertising in Europe 6
4 DTC advertising in the Internet healthcare market 7
5 The growth of online pharmacies 8
5.1 Five categories of the online pharmacy market 8
5.2 Limitations of traditional distribution channels 9
5.3 Advantages of online pharmacies 10
5.4 Challenges and risks facing online pharmacies 11
NEW OPPORTUNITIES IN THE TREATMENT OF OBESITY
Obesity: Executive Summary 75
Chapter 9. Obesity: Market & Technology Overview 77
9.1 The spectre of obesity 77
9.2 Terms used in diagnosis of obesity 78
9.3 Causes of obesity 78
9.4 Risks and consequences of obesity 80
9.5 Nutritional approaches to weight reduction 80
9.6 Surgical intervention in obesity 81
9.7 Traditional pharmacological intervention in obesity 82
9.8 New genetic era in body weight research 84
9.9 Obesity - the full picture 85
Chapter 10. Drugs which Reduce Food Intake 87
10.1 Dopaminergic agents 87
10.2 Serotoninergic drugs 88
10.2.1 5-HT reuptake inhibitors 88
10.2.2 Drugs targeting 5-HT receptor subtypes 88
10.2.3 On the market: Knoll's Meridia 89
10.3 Cholecystokinin (CCK) agonists 89
10.3.1 Other CCK-promoting agents 90
10.4 Leptin and control of its expression 90
10.5 Ciliary neurotrophic factor 91
10.6 Melanocortin-4 receptor agonists 92
10.7 Glucagon-like peptide 1 92
10.8 Corticotropin releasing factor receptor agonists 92
10.9 Neuropeptide y receptor antagonists 93
10.10 Histamine H3 receptor antagonists 94
10.11 Orexin receptor antagonists 94
10.12 Galanin receptor antagonists 94
10.13 Melanin concentrating hormone (MCH) receptor antagonists 95
10.14 Palm and oat oil-derived Olibra 95
10.15 Cactus-derived P57 95
Chapter 11. Drugs which Inhibit Nutrient Absorption 96
11.1 Lipase inhibitors 96
11.1.1 On the market: Roche's Xenical 96
11.2 Alpha-glucosidase inhibitors 97
Chapter 12. Drugs which Increase Energy Expenditure 98
12.1 Alpha2-adrenoceptor antagonists 98
12.2 Beta3-adrenoceptor agonists 99
12.3 Uncoupling proteins l00
Chapter 13. Novel Anti-Obesity Agents 101
13.1 Peroxisome proliferator-activated receptor 101
13.2 18F and other G protein-coupled receptors 101
13.3 CB1 cannabinoid receptor antagonist 102
13.4 Glucose lowering agents 102
13.5 Human steroidal honnone 102
Chapter 14. Profiles of Selected Companies in the Obesity Market 103
Alteon Inc 103
Amgen Inc 104
Arena Pharmaceuticals 105
GelTex Pharmaceuticals Inc 106
Genset 107
Knoll Pharmaceutical Company 108
Ligand Pharmaceuticals Inc 109
Lion Biosciences Inc 110
Millennium Pharmaceuticals 111
Neurocrine Biosciences Inc 112
Neurogen Corp 113
Pfizer Inc 114
Phytophann pIc 115
Regeneron Pharmaceuticals Inc 116
Roche 118
Sanofi-Synthelabo 120
Scotia Holdings pIc 121
Supergen Inc 122
Synaptic Pharmaceutical Corporation 123
Tularik Inc 125
Glossary 130
Chapter 15. Obesity Market: Analysis & Forecasts 131
15.1 World pharmaceutical market by region 2000 131
15.2 Obesity markets 132
Chapter 16. Obesity: Trends & Opportunities 134
16.1 Demand for anti-obesity drugs is high
and available treatments limited 134
16.2 Control of food intake is a popular but
complex therapy target 135
16.3 Interference with fat absorption is viable
but yields modest results 136
16.4 Control of energy expenditure offers
intriguing possibilities 136
16.5 Pharmacogenomics and obesity -
shape of things to come? 137
LIST OF TABLES
Table 7 Drugs which reduce food intake 126
Table 8 Drugs which inhibit nutrient absorption 128
Table 9 Drugs which increase energy expenditure 129
Table 10 Novel anti-obesity agents 130
Table 11 World pharmaceutical market by region 2000 131
Table 12 Selected world markets for anti-obesity
pharmaceuticals, 2000 and 2005 133
|
